{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:43:47Z","timestamp":1793853827395,"version":"4.6.1"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2018.4169","type":"journal-article","created":{"date-parts":[[2018,11,6]],"date-time":"2018-11-06T13:16:30Z","timestamp":1541510190000},"page":"e184169","source":"Crossref","is-referenced-by-count":354,"title":["Association of Immunoglobulin Levels, Infectious Risk, and Mortality With Rituximab and Hypogammaglobulinemia"],"prefix":"10.1001","volume":"1","author":[{"given":"Sara","family":"Barmettler","sequence":"first","affiliation":[{"name":"Allergy and Clinical Immunology Unit, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei-Sing","family":"Ong","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn R.","family":"Farmer","sequence":"additional","affiliation":[{"name":"Allergy and Clinical Immunology Unit, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyon","family":"Choi","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Division of Rheumatology, Allergy & Immunology, Massachusetts General Hospital, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolan","family":"Walter","sequence":"additional","affiliation":[{"name":"Division of Allergy & Immunology, Department of Pediatrics, Massachusetts General Hospital, Boston"},{"name":"Division of Pediatric Allergy\/Immunology, Department of Pediatrics, University of South Florida, Johns Hopkins All Children\u2019s Hospital, St Petersburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2018,11,2]]},"reference":[{"issue":"12","key":"zoi180186r2","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1182\/blood-2016-03-603365","article-title":"How I treat refractory immune thrombocytopenia.","volume":"128","author":"Cuker","year":"2016","journal-title":"Blood"},{"issue":"1","key":"zoi180186r3","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s10875-012-9755-3","article-title":"Use of combination chemotherapy for treatment of granulomatous and lymphocytic interstitial lung disease (GLILD) in patients with common variable immunodeficiency (CVID).","volume":"33","author":"Chase","year":"2013","journal-title":"J Clin Immunol"},{"issue":"2","key":"zoi180186r4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"16","key":"zoi180186r5","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies.","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"issue":"4","key":"zoi180186r6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.coi.2008.05.011","article-title":"Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies.","volume":"20","author":"Taylor","year":"2008","journal-title":"Curr Opin Immunol"},{"issue":"6","key":"zoi180186r7","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera).","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"zoi180186r8","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.jaci.2015.06.035","article-title":"Continuing IgG replacement therapy for hypogammaglobulinemia after rituximab\u2014for how long?","volume":"136","author":"Barmettler","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"zoi180186r9","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1136\/jcp.2009.068940","article-title":"Does rituximab aggravate pre-existing hypogammaglobulinaemia?","volume":"63","author":"Diwakar","year":"2010","journal-title":"J Clin Pathol"},{"issue":"10","key":"zoi180186r10","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment\u2014incidence and outcomes.","volume":"107","author":"Makatsori","year":"2014","journal-title":"QJM"},{"issue":"2","key":"zoi180186r11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"zoi180186r12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","article-title":"Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series.","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"issue":"6","key":"zoi180186r13","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment.","volume":"58","author":"Roll","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"1","key":"zoi180186r14","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"zoi180186r15","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3899\/jrheum.090856","article-title":"Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials.","volume":"37","author":"van Vollenhoven","year":"2010","journal-title":"J Rheumatol"},{"issue":"9","key":"zoi180186r16","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.1002\/(ISSN)1529-0131","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"zoi180186r17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jaip.2014.06.003","article-title":"Rituximab and immune deficiency: case series and review of the literature.","volume":"2","author":"Kaplan","year":"2014","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"zoi180186r18","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1136\/ard.2010.144998","article-title":"Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.","volume":"70","author":"Buch","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"zoi180186r19","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1002\/art.27555","article-title":"Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry.","volume":"62","author":"Gottenberg","year":"2010","journal-title":"Arthritis Rheum"},{"key":"zoi180186r20","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.3389\/fimmu.2017.01740","article-title":"Common variable immunodeficiency non-infectious disease endotypes redefined using unbiased network clustering in large electronic datasets.","volume":"8","author":"Farmer","year":"2018","journal-title":"Front Immunol"},{"key":"zoi180186r21","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1007\/s10875-008-9182-7","article-title":"Autoimmune manifestations in common variable immunodeficiency.","volume":"28","author":"Cunningham-Rundles","year":"2008","journal-title":"J Clin Immunol"},{"key":"zoi180186r22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3389\/fimmu.2012.00189","article-title":"Autoimmune cytopenias in common variable immunodeficiency.","volume":"3","author":"Podjasek","year":"2012","journal-title":"Front Immunol"},{"issue":"2","key":"zoi180186r23","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.clim.2009.05.001","article-title":"Granulomatous disease in common variable immunodeficiency.","volume":"133","author":"Ardeniz","year":"2009","journal-title":"Clin Immunol"},{"key":"zoi180186r24","article-title":"Cancer in primary immunodeficiency diseases: cancer incidence in the United States Immune Deficiency Network Registry.","author":"Mayor","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"22","key":"zoi180186r25","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1182\/blood-2016-11-693689","article-title":"How I treat autoimmune hemolytic anemia.","volume":"129","author":"Go","year":"2017","journal-title":"Blood"},{"issue":"1","key":"zoi180186r26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jaut.2005.04.006","article-title":"Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID).","volume":"25","author":"Wang","year":"2005","journal-title":"J Autoimmun"},{"issue":"4","key":"zoi180186r27","doi-asserted-by":"publisher","first-page":"R131","DOI":"10.1186\/ar2798","article-title":"Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.","volume":"11","author":"Nakou","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"zoi180186r28","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/BOR.0000000000000377","article-title":"Diagnostic and therapeutic considerations in patients with hypogammaglobulinemia after rituximab therapy.","volume":"29","author":"Kado","year":"2017","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"zoi180186r29","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/art.40032","article-title":"Effect of continuous B cell depletion with rituximab on pathogenic autoantibodies and total IgG levels in antineutrophil cytoplasmic antibody\u2013associated vasculitis.","volume":"69","author":"Cortazar","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"zoi180186r30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab.","volume":"36","author":"Christou","year":"2017","journal-title":"Int Rev Immunol"},{"key":"zoi180186r1"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/\/jamanetworkopen\/article-pdf\/1\/7\/e184169\/17295068\/barmettler_2018_oi_180186.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T12:24:55Z","timestamp":1550147095000},"score":1,"resource":{"primary":{"URL":"http:\/\/jamanetworkopen.jamanetwork.com\/article.aspx?doi=10.1001\/jamanetworkopen.2018.4169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,2]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,11,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,2]]}}}